Sobi's profit jumps, guidance raised, and new rare-disease deals expand pipeline
FDA rejects gout drug NASP over manufacturing issues The FDA sent a complete response letter for Sobi's gout treatment NASP, asking for more manufacturing data. No clinical safety or efficacy problems were found, but approval is delayed. This pushes the share price down because a near-term launch is now uncertain.
This is a fresh regulatory setback that delays a potential new product and weighs on the stock.
Canada backs EMPAVELI for rare kidney diseases Canada's drug agency gave a positive reimbursement recommendation for EMPAVELI in two rare kidney conditions. This opens a new market for Sobi's drug, which is already approved elsewhere. It lifts the share price by adding a new source of sales growth.
This is a new market-access win that expands demand for an existing Sobi product.
Q2 profit surges and 2026 outlook raised Sobi reported much higher second-quarter profit and revenue, and raised its full-year 2026 guidance for both sales growth and profit margin. This boosts the share price because it shows the core business is performing better than expected and management is more confident.
This is a new earnings beat and guidance raise that directly improves investor expectations for future profits.
Sobi-Innate lacutamab partnership becomes effective Sobi's partnership with Innate Pharma for the cancer drug lacutamab closed, triggering a $75 million payment from Sobi. The deal gives Sobi global commercial rights and a path to accelerated approval. It lifts the share price by adding a late-stage pipeline asset with blockbuster potential.
This is a new closing of a strategic deal that expands Sobi's pipeline and future revenue prospects.